Novotech and Biostar establish strategic partnership following Biostar’s HKEX listing

Novotech, the global full-service clinical Contract Research Organisation (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has announced a long-term strategic partnership with Beijing Biostar Pharmaceuticals Co. This collaboration strengthens the commitment of both companies to advance clinical research, leveraging Novotech’s expertise and technical platforms to support Biostar’s clinical development plans.

Biostar, a leader in synthetic biology and oncology development in China, recently marked a significant milestone with its successful listing on the Hong Kong Stock Exchange, symbolising a new phase of growth.

Dr Li Tang, Chairman, Executive Director, Chief Scientific Officer, and Chief Marketing Officer of Biostar, stated, “As a biopharmaceutical company driven by synthetic biology technology, Biostar is committed to developing innovative oncology drugs. Our successful listing is a major milestone in our development and a new beginning. Going forward, we will continue to focus on research and innovation, bring more innovative drug products to market, and extend our current products to more patients, contributing significantly to the health and wellness sector.”

Andy Liu, General Manager of Novotech China, added, “As a strategic partner in Biostar’s research phase, we are confident in our future collaboration and look forward to supporting Biostar as it expands into international markets, bringing more innovative and advanced health solutions to a global audience.”

This strategic partnership highlights Novotech’s commitment to partnering with biotech innovators in their journey from development to market, reinforcing the company’s role as a trusted CRO in the global clinical research landscape.